Premenstrual dysphoric disorder: is there an economic burden of illness?
The economic burden associated with PMDD manifests itself primarily in reported productivity decrements rather than health care utilization or costs associated with time away from work.
The take-home message is that there is a clear process of progressive diversification concerning the antibody expression platforms and an effort to yield directly application-adapted immune-reagents rather than generic naked antibodies that need further in vitro modification steps before becoming usable.